Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: GlobalData
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc lowers FY 2014 EBIT outlook

Thursday, 7 Aug 2014 07:32am EDT 

Sarepta Therapeutics Inc:Expects FY 2014 Non-GAAP loss from operations will range from $135 to $145 mln, as compared with its previous guidance of $110 to $120 mln.FY 2014 EBIT of $(122) mln - Thomson Reuters I/B/E/S. 

Company Quote

0.04 +0.29%
26 Dec 2014